Urgent warning for parents: Deadly nicotine poisonings in kids are skyrocketing
From 2010 through 2023, U.S. poison centers reported 134,663 cases of nicotine poisonings among kids under age 6, according to a study published Monday in Pediatrics, a journal of the American Academy of Pediatrics.
Nearly all occurred at home.
The cases included exposures to nicotine pouches, chewing tobacco, regular cigarettes, vapes and nicotine replacement products like gum and lozenges.
But it's nicotine pouches, like the wildly popular Zyn, that are behind the most significant rise in accidental nicotine poisonings among young kids.
The new research found that the rate of poisonings involving nicotine pouches among kids under 6 rose from 0.48 per 100,000 children in 2020 to 4.14 per 100,000 in 2023.
That's an increase of 763% in just three years — a startling finding that correlates with a surge in sales of nicotine pouches.
Nicotine pouches — which users tuck between their lip and gum and later discard — can contain as much as 6 milligrams of nicotine, a stimulant, and have been promoted as tobacco-free, spit-free and hands-free alternatives to cigarettes and chewing tobacco.
They are not, however, approved by the Food and Drug Administration as nicotine replacement products used to help quit smoking.
A 2021 study from the Centers for Disease Control and Prevention's Office on Smoking and Health (one of several public health groups dismantled under the Trump administration) found that sales of nicotine pouches rose dramatically in the past decade, from $709,000 in 2016 to $216 million by mid-2020.
'It was just a matter of time before they fell into the hands of younger kids,' said Dr. Molly O'Shea, a Michigan pediatrician and spokesperson for the American Academy of Pediatrics. 'It's unfortunate, but not shocking.'
Nicotine is a chemical that's highly toxic and could easily exceed a fatal dose in small children, according to a 2013 study.
The chemical increases heart rate and blood pressure, and could lead to nausea, vomiting or even coma, the study authors wrote.
Most cases included in the new research weren't serious enough to warrant medical attention. But 39 children had significant side effects, like trouble breathing and seizures, said Natalie Rine, an author of the new study and director of the Central Ohio Poison Center at Nationwide Children's Hospital in Columbus.
Most nicotine poisoning cases, 76%, were babies and toddlers under age 2.
Two children, a 1-year-old boy and another boy about a year and a half old, died after ingesting liquid nicotine used in vapes.
'It's good that the majority of kids in the study actually did pretty well. Most kids had either minor symptoms or no symptoms and didn't require any medical management,' Rine said. 'But two deaths is a lot, especially for something considered a preventable death.'
Kids are curious by nature. Babies and toddlers in particular explore their worlds by putting things in their mouth.
And they're masters at breaking into drawers and cabinets to find new 'toys.' Canisters of nicotine pouches are not equipped with child-resistant packaging. They taste good, too. Mint and fruit flavors are almost always added.
O'Shea said it's critical that all nicotine products are placed far out of reach of children. 'That doesn't mean in your purse, in your back pocket or on the counter,' she said. 'It means locked away.'
It's not just parents and other adult caregivers who must be mindful of their nicotine products. An April study from the Keck School of Medicine of the University of Southern California found the use of nicotine pouches among high school students nearly doubled between 2023 and 2024.
'It's easy for a teenager to be using this product and have parents be unaware,' O'Shea said. 'It's important for parents to be talking with their teenagers about products like this and having open dialogue in a nonjudgmental way in order to ascertain any risk.'
Rine also recommends adding the national poison control number to cellphones: 1-800-222-1222.
This article was originally published on NBCNews.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
ComPsych Relocates Global Headquarters to Prudential Plaza in Chicago
CHICAGO, July 14, 2025--(BUSINESS WIRE)--ComPsych® Corporation, the worldwide leader in organizational mental health, well-being, and absence management, today celebrated the relocation of its global corporate headquarters to One Prudential Plaza located at 130 E. Randolph Street in Chicago. The 50,000-square foot space provides ample room for both Chicago-based and visiting employees to work and collaborate, including a state-of-the-art media production studio, modern conference rooms and open air collaboration zones, as well as robust building amenities and the ability to host large scale in-person gatherings. Additionally, every work station features adaptable, ergonomic furniture, aligning with ComPsych's corporate focus on holistic well-being. The move follows a string of major updates from the company in 2025, including the launch of a new corporate brand, a reimagined digital experience of its flagship product GuidanceResources Online, the exponential expansion of its library of dynamic mental health resources, and the introduction of numerous self-service enhancements and automations to streamline the customer experience in AbsenceResources (formerly FMLASource). "We're barely half-way through, but already 2025 has been a banner year for ComPsych," said CEO Paul Posey. "And there's much more on the horizon. Our new corporate headquarters at Prudential Plaza will help us foster a vibrant, collaborative culture so we can continue to innovate and better support the more than 160 million people our services touch around the world." "As the industry leader in employee behavioral health, well-being, absence, and work-life services, we know the importance of empowering our team through freedom and flexibility," continued Posey. "Our workspace is adapting to support and inspire our modern workforce. We're proud that our new global headquarters prioritizes shared, social and collaboration spaces – creating an environment where our team members want to be – while still trusting every individual staff member to know where and how they'll work best." "ComPsych has been a pillar of the Chicago business community for decades, and we're thrilled to have represented them in their relocation to Prudential Plaza," said Brian Means, Executive Vice President at JLL. "We know the recent renovations made to the building, the desirable location next to Millennium Park, and the extensive amenities will make it the perfect place as ComPsych focuses on its mission to ignite human potential in workplaces worldwide," added Kellen Monti, Senior Vice President at JLL. For more information on ComPsych, please visit About ComPsych ComPsychⓇ is the worldwide leader in organizational mental health, well-being, and absence management, dedicated to igniting human potential in workplaces across the globe. For over 40 years, we have combined the best in technology with unmatched human expertise to help individuals and their organizations thrive. Our GuidanceResourcesⓇ and AbsenceResourcesⓇ solutions deliver end-to-end mental health, well-being, work-life, health navigation, and absence support to more than 75,000 customers worldwide, touching more than 160 million lives across 200 countries. Visit to find out why 40% of the Fortune 500 choose ComPsych for their mental health and absence management needs. View source version on Contacts Press ContactCarolyn Linckclinck@ (312) 446-0339 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Pennsylvania Senate passes bill to expand no-cost breast cancer diagnostics
HARRISBURG, Pa. (WHTM) — Pennsylvania Senate leaders met Tuesday to celebrate the unanimous passage of Bill 88, which expands no-cost breast cancer diagnostics. The bill, sponsored by Sen. Frank Farry (R-Bucks), expands on a previous law requiring insurance companies to cover breast cancer screenings for high-risk women. It clarifies that insurance companies must cover screenings and diagnostics with no out-of-pocket costs for not just high-risk women but average-risk women, too. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now 'There's a lot of folks that don't go to the doctors, they don't check for lumps, because they can't afford to go to a doctor,' said Sen. Christine Tartaglione (D-Philadelphia). 'So now with today's legislation, Senate Bill 88, they don't have to worry about it, the barrier is gone.' Senators are still looking ahead to push for continued funding for breast cancer screening. The bill now heads to the House for consideration. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing. Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. Through its AD-Detect™ portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings. "Our goal is to advance access to quality and innovative blood-based tests for Alzheimer's disease. Adding the Fujirebio test to our existing blood-based tests provides the many physicians we serve with another powerful option for assessing patients for Alzheimer's disease," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics. "Blood-based testing can be less invasive and more convenient than traditional test methods. We are excited to leverage our expansive network of patient service centers to broaden access to the Fujirebio innovation to help more at-risk individuals gain access to the insights they need sooner." In a clinical study population of 499 patients, which closely mirrors US demographics, and when applying a dual cut point, the FDA-cleared test demonstrated a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 97%, with 20% of patients uncertain to have amyloid pathology, thus requiring further testing. Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31. "As brain health and Alzheimer's disease interventions continue to evolve, diagnosing patients earlier, when interventions can be most effective, is critical," said Michael Racke, MD, a board-certified neurologist and Medical Director of Neurology, Quest Diagnostics. "We are constantly looking for ways to help physicians and patients make the most informed decisions, and this new addition to our test menu will aid that goal." While amyloid PET imaging and cerebral spinal fluid testing are established methods for aiding the diagnosis of Alzheimer's disease, they are significantly more expensive, invasive and specialist-dependent than blood-based tests. With a physician's order, patients can conveniently provide a blood draw for testing for the Fujirebio test and any of the AD-Detect™ tests through Quest's network of patient sites. Quest maintains approximately 8,000 patient access points, including an extensive patient service center network of approximately 2,000 locations in the U.S., as well as phlebotomists in physician offices and mobile phlebotomy services. Specimens will be transported for testing to Quest's state-of-the-art laboratory in San Juan Capistrano, California. Nearly 7 million Americans have Alzheimer's, the most prevalent dementia, a number projected to reach 14 million by 2060. Approximately 12-18% of adults over the age of sixty are living with mild cognitive impairment, a potential sign of AD. Seventy-seven percent of physicians say new therapies will transform Alzheimer's into a chronic, manageable disease, and 94% of physicians say blood tests would be more cost effective for the healthcare system compared to more invasive methods of detection (e.g., lumbar puncture, imaging studies) according to a special report from Quest. Quest is committed to developing and offering innovative advanced diagnostics to aid in evaluating Alzheimer's disease and other brain diseases. For more information, visit About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. View original content to download multimedia: SOURCE Quest Diagnostics